Skip to main content

From the Helm: CSL’s David Lamont on the biotech giant’s bright future

Jessica Amir
February 20, 2020

In the latest instalment of Bell Direct’s From the Helm series, Jess has a chat with CSL’s CFO David Lamont.

David gives the inside scoop on CSL, the market leader in the blood plasma and vaccine market. Additionally, he explains CSL’s own products, programmes and partnerships, and the steps taken by the medical giant to tackle coronavirus.

Plus, he sheds some light on the unique situation the broader pharmaceuticals industry finds itself in when it comes to new competition, as well as CSL’s future proofing strategy.

Equity Investor 29 Jan

Julia Lee
January 30, 2018

Reporting season preview

Julia Lee
January 29, 2018

Market Update

Julia Lee
January 25, 2018

Market Update

Julia Lee
January 24, 2018

Market Update

Julia Lee
January 23, 2018

Market Update

Julia Lee
January 22, 2018

Market Update

Julia Lee
January 22, 2018

Market Update

Julia Lee
January 17, 2018

Your Money Your Call 16 January

Julia Lee
January 17, 2018

Market Update

Julia Lee
January 12, 2018

Market Update

Julia Lee
January 10, 2018